History of significant bleeding disorder unrelated to chronic myelogenous leukemia (CML), including:\r\n* Diagnosed congenital bleeding disorders (e.g. von Willebrand’s disease) \r\n* Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor VII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\r\n* Ongoing or recent (=< 3 months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including: \r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s’ disease) \r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) \r\n* History of gastrointestinal (GI) bleeding within one year
History of significant bleeding disorder unrelated to cancer, including: 1) diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease); 2) diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of screening visit; 3) history of gastrointestinal (GI) bleeding within 3 months of screening visit requiring >= 2 units packed red blood cells.
History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease); diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease, diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies, or ongoing or recent (=< 3 months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including: Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease); and diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
No abnormalities no history of diagnosed acquired bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies) of registration on protocol therapy
Patients meeting the following criteria are not eligible unless cleared by cardiology: \r\n* Uncontrolled angina within 3 months\r\n* Diagnosed or suspected congenital long QT syndrome\r\n* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)\r\n* Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 460 msec) \r\n* History of significant bleeding disorder unrelated to cancer, including: \r\n** Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease) \r\n** Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\r\n* Ongoing or recent (=< 3 months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease), or diagnosed acquired bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Known bleeding disorders with the exception of acquired Von Willebrand disorder suspected on the basis of WM
Concurrent medical conditions or injury which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), history of human immunodeficiency virus (HIV)-positive, or active or chronic hepatitis C and/or B infection
Concurrent medical conditions which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), human immunodeficiency virus (HIV)-positive
History of significant bleeding disorder unrelated to cancer, including: congenital bleeding disorders (e.g, von Willebrand's disease), acquired bleeding disorder within the past 12 months (e.g, acquired anti-factor VIII antibodies, including any ongoing or recent less than or equal to 3 months), significant gastrointestinal bleeding, or use of oral anticoagulant therapy
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\r\n* Ongoing or recent (=< 3 months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including: · Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease) · Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of Screening visit
History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease), diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)